Background
Methods
Literature search and inclusion criteria
Quality assessment
Data extractions and syntheses
Heterogeneity analysis
Risk of publication bias
Results
Study selection and inclusion
Included trials | Country | Study design | Eligibility criteria | Gender (male/female); mean age (years) | Migraine-days (hours) per month | Interventions drug | Course of treatment | Main efficacy outcomes | Most frequent adverse events | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Trial | Control | Trial | Control | ||||||||
David W Dodick et al., 2014 (1) [37] | USA | RCT | ICHD-II 2004 | 19/88; 40.9 ± 11.4 | 14/96; 41.9 ± 11.7 | 6.7 ± 2.4 | 7.0 ± 2.5 | LY2951742 (150 mg) | 12 weeks | The reduction of monthly migraine days; 50%, 75%, and 100% responder rate | Injection site pain, nasopharyngitis, respiratory infection, nausea, and so on. |
David W Dodick et al., 2014 (2) [38] | USA | RCT | ICHD-II 2004 | 14/67; 38.6 ± 10.8 | 16/66; 39.0 ± 9.6 | 8.4 ± 2.1 | 8.8 ± 2.7 | ALD403 (1000 mg) | 24 weeks | The reduction of monthly migraine days; 50%, 75%, and 100% responder rate; HIT-6; MSQ | Respiratory and urinary infection, back pain, nausea, and so on. |
Hong Sun et al., 2016 [39] | USA | RCT | ICHD-II 2004 | 25/82; 42.6 ± 9.9 | 28/132; 41.4 ± 10.0 | 8.6 ± 2.5 | 8.8 ± 2.7 | AMG 334 (7/21/70 mg) | 12 weeks | The reduction of monthly migraine days; 50% responder rate; MIDAS; MSQ; HIT-6; PROMIS | Upper respiratory tract infection, back pain, nausea, and so on. |
Marcelo E Bigal et al., 2015 (1) [35] | USA | RCT | ICHD-3 2013 | 15/82; 40.7 ± 12.6 | 12/92; 42.0 ± 11.6 | 80.4 ± 36.6 (hours) | 82.1 ± 49.3 (hours) | TEV-48125 (225/675 mg) | 12 weeks | The reduction of monthly migraine days; 50% and 75% responder rate | Upper respiratory tract infection, back pain, nausea, and so on. |
Marcelo E Bigal et al., 2015 (2) [36] | USA | RCT | ICHD-3 2013 | 12/75; 41.5 ± 12.9 | 13/76; 40.7 ± 11.5 | 16.4 ± 5.3 | 16.8 ± 5.0 | TEV-48125 (225/675/900 mg) | 12 weeks | The reduction of monthly migraine days; 50% and 75% responder rate | Back pain, nasopharyngitis, injection-site pain, and so on. |